Stockreport

Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]

Larimar Therapeutics, Inc.  (LRMR) 
PDF $244.5 million in pro forma cash, cash equivalents and marketable securities as of December 31, 2025, with projected cash runway into the second quarter of 2027 Fresh [Read more]